Take Homes in Gynecologic Cancer

Take Homes in Gynecologic Cancer

Source:

Zola P, et al. Abstract 5506. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Annunziata reports no relevant financial disclosures.
July 22, 2021
1 min watch
Save

VIDEO: Less intense follow-up adequate in endometrial cancer

Source:

Zola P, et al. Abstract 5506. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Annunziata reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed results from the TOTEM trial presented at the ASCO Annual Meeting.

Researchers designed TOTEM to compare intensive follow-up with minimalist follow-up in patients who were surgically treated for endometrial cancer and were in complete clinical remission. They stratified patients according to whether they had a low or high risk for recurrence and then randomly assigned patients to intensive or minimalist follow-up regimens.

In both high- and low-risk patients, intensive follow-up did not appear to improve survival compared with minimalist follow-up.

“This also has implications for how patients are followed up after diagnosis of endometrial cancer,” Annunziata said.